Cancerimmunterapi

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Cancerimmunterapi. / Kjeldsen, Julie Westerlin; Donia, Marco; Svane, Inge Marie.

In: Ugeskrift for Laeger, Vol. 180, V09170691, 2018.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Kjeldsen, JW, Donia, M & Svane, IM 2018, 'Cancerimmunterapi', Ugeskrift for Laeger, vol. 180, V09170691. <http://ugeskriftet.dk/videnskab/cancerimmunterapi>

APA

Kjeldsen, J. W., Donia, M., & Svane, I. M. (2018). Cancerimmunterapi. Ugeskrift for Laeger, 180, [V09170691]. http://ugeskriftet.dk/videnskab/cancerimmunterapi

Vancouver

Kjeldsen JW, Donia M, Svane IM. Cancerimmunterapi. Ugeskrift for Laeger. 2018;180. V09170691.

Author

Kjeldsen, Julie Westerlin ; Donia, Marco ; Svane, Inge Marie. / Cancerimmunterapi. In: Ugeskrift for Laeger. 2018 ; Vol. 180.

Bibtex

@article{74d710278434407396b7ee55984e0a95,
title = "Cancerimmunterapi",
abstract = "Cancer immunotherapy takes advantage of the immune system to treat cancer. The checkpoint inhibitors have advanced the field of cancer treatment, but adoptive cell therapy and cancer vaccines also show promising results. The checkpoint inhibitors ipilimumab and later nivolumab/pembrolizumab have been standard therapy to patients with metastatic melanoma for several years. Today, the field is expanding, and other types of solid tumours have had checkpoint inhibitors applied to them, and more will follow. A portion of the patients develop immune-related adverse events, which should be handled by specialists.",
author = "Kjeldsen, {Julie Westerlin} and Marco Donia and Svane, {Inge Marie}",
year = "2018",
language = "Dansk",
volume = "180",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",

}

RIS

TY - JOUR

T1 - Cancerimmunterapi

AU - Kjeldsen, Julie Westerlin

AU - Donia, Marco

AU - Svane, Inge Marie

PY - 2018

Y1 - 2018

N2 - Cancer immunotherapy takes advantage of the immune system to treat cancer. The checkpoint inhibitors have advanced the field of cancer treatment, but adoptive cell therapy and cancer vaccines also show promising results. The checkpoint inhibitors ipilimumab and later nivolumab/pembrolizumab have been standard therapy to patients with metastatic melanoma for several years. Today, the field is expanding, and other types of solid tumours have had checkpoint inhibitors applied to them, and more will follow. A portion of the patients develop immune-related adverse events, which should be handled by specialists.

AB - Cancer immunotherapy takes advantage of the immune system to treat cancer. The checkpoint inhibitors have advanced the field of cancer treatment, but adoptive cell therapy and cancer vaccines also show promising results. The checkpoint inhibitors ipilimumab and later nivolumab/pembrolizumab have been standard therapy to patients with metastatic melanoma for several years. Today, the field is expanding, and other types of solid tumours have had checkpoint inhibitors applied to them, and more will follow. A portion of the patients develop immune-related adverse events, which should be handled by specialists.

M3 - Tidsskriftartikel

C2 - 29804567

VL - 180

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

M1 - V09170691

ER -

ID: 215789659